Suppr超能文献

kratom是街区上新出现的“合法兴奋剂”吗?:一种具有药物滥用潜力的新型阿片受体激动剂的案例。

Is Kratom the New 'Legal High' on the Block?: The Case of an Emerging Opioid Receptor Agonist with Substance Abuse Potential.

作者信息

Chang-Chien George C, Odonkor Charles A, Amorapanth Prin

机构信息

Ventura County Medical Center, Ventura CA.

出版信息

Pain Physician. 2017 Jan-Feb;20(1):E195-E198.

Abstract

Kratom is an unscheduled opioid receptor agonist that comes in the form of dietary supplements currently being abused by chronic pain patients on prescription opioids. Active alkaloids isolated from kratom such as mitragynine and 7-hydroxymitragynine are thought to act on mu- and delta-opioid receptors as well as alpha-2 adrenergic and 5-HT2A receptors. Animal studies suggest that kratom may be more potent than morphine. Consequently, kratom consumption produces analgesic and euphoric feelings among users. In particular, some chronic pain patients on opioids take kratom to counteract the effects of opioid withdrawal. Although the Food and Drug Administration has banned its use as a dietary supplement, kratom continues to be widely available and easily accessible on the Internet at much less expensive rates than some opioid replacement therapies like buprenorphine. There are no federal regulations monitoring the sale and distribution of this drug, yet kratom has been associated with severe signs and symptoms such as hallucinations, delusions, depressions, myalgias, chills, nausea/vomiting, respiratory hepatoxicity, seizures, coma, and death. A search of the pain literature shows past research has not described the use and potential deleterious effects of this drug. Many pain physicians are not familiar with kratom and as providers who take care of high-risk chronic pain patients using prescribed opioids, knowledge of current unregulated opioid receptor agonists with abuse potential is of paramount importance. The goal of this article is to introduce kratom to pain specialists and to spur a conversation on how pain physicians may take the lead to help curb the opioid abuse and overdose epidemic. Further studies may be required to help better understand the clinical and long-term effects of kratom use among chronic pain patients.Key words: Opioid receptor agonist, Kratom, Mitragynine, opioid overdose, chronic pain, substance abuse.

摘要

kratom是一种未被列入管制的阿片受体激动剂,以膳食补充剂的形式存在,目前正被使用处方阿片类药物的慢性疼痛患者滥用。从kratom中分离出的活性生物碱,如帽柱木碱和7-羟基帽柱木碱,被认为作用于μ-和δ-阿片受体以及α-2肾上腺素能受体和5-HT2A受体。动物研究表明,kratom可能比吗啡更有效。因此,服用kratom会在使用者中产生镇痛和欣快感。特别是,一些服用阿片类药物的慢性疼痛患者服用kratom来抵消阿片类药物戒断的影响。尽管美国食品药品监督管理局已禁止将其用作膳食补充剂,但kratom在互联网上仍然广泛可得且易于获取,其价格比某些阿片类替代疗法(如丁丙诺啡)便宜得多。目前没有联邦法规监管这种药物的销售和分销,但kratom已与严重的体征和症状相关联,如幻觉、妄想、抑郁、肌痛、寒战、恶心/呕吐、呼吸性肝毒性、癫痫发作、昏迷和死亡。对疼痛文献的检索显示,过去的研究尚未描述这种药物的使用及其潜在的有害影响。许多疼痛科医生不熟悉kratom,作为照顾使用处方阿片类药物的高危慢性疼痛患者的医疗服务提供者,了解当前具有滥用潜力的未受管制的阿片受体激动剂至关重要。本文的目的是向疼痛专家介绍kratom,并引发一场关于疼痛科医生如何带头帮助遏制阿片类药物滥用和过量流行的讨论。可能需要进一步的研究来更好地了解kratom在慢性疼痛患者中的临床和长期影响。关键词:阿片受体激动剂;kratom;帽柱木碱;阿片类药物过量;慢性疼痛;药物滥用

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验